Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2
MetadataShow full item record
CitationPlotkin, Scott R., Vanessa L. Merker, Chris Halpin, Dominique Jennings, Michael J. McKenna, Gordon J. Harris, and Fred G. Barker. 2012. “Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2.” Otology & Neurotology 33 (6) (August): 1046–1052. doi:10.1097/mao.0b013e31825e73f5.
AbstractObjective: Early studies suggest that bevacizumab treatment can result in tumor shrinkage and hearing improvement for some patients with neurofibromatosis type 2 (NF2). The aim of this study was to report extended follow-up in a larger cohort of similarly treated patients.
Study Design: Retrospective study.
Setting: Tertiary referral center
Patients: Thirty-one consecutive NF2 patients who received bevacizumab for progressive vestibular schwannomas.
Main Outcome Measure: Hearing improvement, defined as an improvement in word recognition score above the 95% critical difference compared with baseline, and radiographic response, defined as a 20% or greater decrease in tumor volume compared with baseline.
Results: The median age was 26 years (range, 12–73 yr). The median volumetric tumor growth rate before treatment was 64% per year. At the time of analysis, the median duration of treatment was 14 months (range, 6–41 mo) with a total of 47 patient-years of follow-up. A hearing response occurred in 57% (13/23) of evaluable patients and a radiographic response in 55% (17/31) of target vestibular schwannomas. The median time to response was 3 months for both end points. The only clinical or radiographic feature at baseline that correlated with change in tumor volume at 3 months was the mean apparent diffusion coefficient value, a radiologic marker of edema (p = 0.036). Ninety percent of patients had stable or improved hearing after 1 year of treatment and 61% at 3 years; 88% of patients had stable or decreased tumor size after 1 year of treatment and 54% at 3 years. Overall, treatment was well tolerated.
Conclusion: Bevacizumab treatment was followed by hearing improvement and tumor shrinkage in more than 50% of progressive vestibular schwannomas in NF2 patients. Stable or improved hearing was retained in the majority of patients.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:33788498
- HMS Scholarly Articles